Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor antigen presentation: changing the rules

T D Armstrong1, B A Pulaski, S Ostrand-Rosenberg

  • 1Department of Biological Sciences, University of Maryland, Baltimore 21250, USA.

Cancer Immunology, Immunotherapy : CII
|April 29, 1998
PubMed
Summary

Cell-based tumor vaccines aim for direct antigen presentation. However, CD8+ T cell activation relies on cross-priming, while CD4+ T cells use direct presentation, impacting anti-cancer vaccine development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Susceptibility of allogeneic mice to teratocarcinoma 402AX.

Immunogenetics·2012
Same author

Mouse 4T1 breast tumor model.

Current protocols in immunology·2008
Same author

Mouse SaI sarcoma tumor model.

Current protocols in immunology·2008
Same author

H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.

Traffic (Copenhagen, Denmark)·2001
Same author

Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.

Journal of immunology (Baltimore, Md. : 1950)·2000

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cell-based tumor vaccines are designed to elicit anti-tumor immune responses.
  • The underlying hypothesis involves genetically modified tumor cells presenting antigens directly to T lymphocytes.

Purpose of the Study:

  • To investigate the primary pathways for T cell activation in response to cell-based tumor vaccines.
  • To understand the distinct roles of antigen presentation in CD8+ versus CD4+ T cell responses.

Main Methods:

  • Utilizing genetically modified tumor cells for vaccine development.
  • Analyzing T lymphocyte activation pathways in the context of tumor antigen presentation.

Main Results:

  • Cross-priming is the predominant mechanism for activating tumor-specific CD8+ T cells.
  • Direct antigen presentation by tumor cells primarily drives the activation of tumor-specific CD4+ T cells.

Conclusions:

  • The findings reveal a paradox in immune response generation for anti-cancer vaccines.
  • These results have significant implications for the rational design and optimization of future cancer immunotherapies.

Related Experiment Videos